| Target Price | HK$2.87 |
| Price | HK$1.77 |
| Potential |
62.68%
register free of charge
|
| Number of Estimates | 4 |
|
4 Analysts have issued a price target Luye Pharma Group 2027 .
The average Luye Pharma Group target price is HK$2.87.
This is
62.68%
register free of charge
HK$3.47
96.32%
register free of charge
HK$2.35
33.33%
register free of charge
|
|
| A rating was issued by 8 analysts: 6 Analysts recommend Luye Pharma Group to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Luye Pharma Group stock has an average upside potential 2027 of
62.68%
register free of charge
|
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Billion HK$ | 7.39 | 7.36 |
| 4.07% | 0.39% | |
| EBITDA Margin | 33.52% | 30.89% |
| 3.68% | 7.83% | |
| Net Margin | 9.81% | 11.35% |
| 25.99% | 15.72% |
4 Analysts have issued a sales forecast Luye Pharma Group 2026 . The average Luye Pharma Group sales estimate is
This results in the following potential growth metrics:
4 Luye Pharma Group Analysts have issued a net profit forecast 2026. The average Luye Pharma Group net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share HK$ | 0.16 | 0.21 |
| 6.67% | 31.25% | |
| P/E | 8.45 | |
| EV/Sales | 1.24 |
4 Analysts have issued a Luye Pharma Group forecast for earnings per share. The average Luye Pharma Group EPS is
This results in the following potential growth metrics and future valuations:
Luye Pharma Group...
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


